142 related articles for article (PubMed ID: 32566235)
1. Dipeptidyl Peptidase-4 inhibitors use in type II diabetic patients in a tertiary hospital.
Mak WY; Nagarajah JR; Abdul Halim H; Ramadas A; Mohd Pauzi Z; Pee LT; Jagan N
J Pharm Policy Pract; 2020; 13():34. PubMed ID: 32566235
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent.
Tang YZ; Wang G; Jiang ZH; Yan TT; Chen YJ; Yang M; Meng LL; Zhu YJ; Li CG; Li Z; Yu P; Ni CL
Diabetol Metab Syndr; 2015; 7():91. PubMed ID: 26500706
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of DPP4i as the Fourth Drug in the Management of Type2 Diabetes Mellitus in Asian Indians Poorly Controlled by Use of at least 3 Oral Antidiabetic Drugs.
Panikar V; Joshi S; Tiwaskar M; Vadgama J; Nasikkar N; Kamat T; Deogaonkar N; Walawalkar S; Sachdev I; Jain C; Modh K; Panikar K; Kulkarni P; Medidar R
J Assoc Physicians India; 2019 Aug; 67(8):60-62. PubMed ID: 31562719
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents.
Li CJ; Liu XJ; Bai L; Yu Q; Zhang QM; Yu P; Yu DM
Diabetol Metab Syndr; 2014; 6():69. PubMed ID: 24917890
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Scheen AJ
Clin Pharmacokinet; 2010 Sep; 49(9):573-88. PubMed ID: 20690781
[TBL] [Abstract][Full Text] [Related]
6. Durability of Effectiveness Between Users of Once-Weekly Semaglutide and Dipeptidyl Peptidase 4 Inhibitors (DPP-4i) in US Adults with Type 2 Diabetes.
Tan X; Liang Y; Gamble C; King A
Diabetes Ther; 2024 Feb; 15(2):427-445. PubMed ID: 38060149
[TBL] [Abstract][Full Text] [Related]
7. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I
Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.
Richter B; Bandeira-Echtler E; Bergerhoff K; Lerch CL
Cochrane Database Syst Rev; 2008 Apr; 2008(2):CD006739. PubMed ID: 18425967
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety profile of sitagliptin, vildagliptin, and metformin in newly diagnosed type 2 diabetic subjects.
Elhini SH; Hussien AK; Omran AAE; Elsayed AA; Saeed H
Clin Exp Pharmacol Physiol; 2021 Dec; 48(12):1589-1602. PubMed ID: 34333803
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of evogliptin for type 2 diabetes mellitus: A systematic review and meta-analysis.
Tang Q; Pan W; Peng L
Front Endocrinol (Lausanne); 2022; 13():962385. PubMed ID: 36060938
[TBL] [Abstract][Full Text] [Related]
11. Comparative Effects of Metformin and Dipeptidyl Peptidase-4 Inhibitors in Japanese Obese Patients with Type 2 Diabetes: A Claims Database Study.
Odawara M; Aoi S; Takeshima T; Iwasaki K
Diabetes Ther; 2021 Aug; 12(8):2165-2177. PubMed ID: 34218420
[TBL] [Abstract][Full Text] [Related]
12. Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment.
Thomas MC; Paldánius PM; Ayyagari R; Ong SH; Groop PH
Diabetes Ther; 2016 Sep; 7(3):439-54. PubMed ID: 27502495
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Cardiovascular Safety of DPP-4 Inhibitors.
Subrahmanyan NA; Koshy RM; Jacob K; Pappachan JM
Curr Drug Saf; 2021; 16(2):154-164. PubMed ID: 32819262
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus.
Chen XW; He ZX; Zhou ZW; Yang T; Zhang X; Yang YX; Duan W; Zhou SF
Clin Exp Pharmacol Physiol; 2015 Oct; 42(10):999-1024. PubMed ID: 26173919
[TBL] [Abstract][Full Text] [Related]
15. A ProspectIve, OpeN-Label, Randomized Study Comparing EffIcacy and Safety of Teneligliptin VErsus Sitagliptin in Indian Patients with Inadequately Controlled Type 2 Diabetes Mellitus: INSITES Study.
Mohan V; Ramu M; Poongothai S; Kasthuri S
J Assoc Physicians India; 2019 Oct; 67(10):14-19. PubMed ID: 31571445
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
Penno G; Garofolo M; Del Prato S
Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869
[TBL] [Abstract][Full Text] [Related]
17. A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors.
Izumi K; Nishie W; Beniko M; Shimizu H
Front Immunol; 2019; 10():1439. PubMed ID: 31297116
[No Abstract] [Full Text] [Related]
18. Dose adjustment of metformin and dipeptidyl-peptidase IV inhibitors in diabetic patients with renal dysfunction.
Melzer-Cohen C; Karasik A; Leuschner PJ; Azuri J; Shalev V; Chodick G
Curr Med Res Opin; 2018 Oct; 34(10):1849-1854. PubMed ID: 29611727
[TBL] [Abstract][Full Text] [Related]
19. Demographic and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Initiating Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Study of UK General Practice.
Tebboth A; Lee S; Scowcroft A; Bingham-Gardiner P; Spencer W; Bolodeoku J; Hassan SW
Clin Ther; 2016 Aug; 38(8):1825-1832.e15. PubMed ID: 27491279
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus.
Duvnjak L; Blaslov K
Diabetol Metab Syndr; 2016; 8():26. PubMed ID: 27006706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
